As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
This article was originally published in The Pink Sheet Daily
Executive Summary
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.
You may also be interested in...
Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from FDA's Import Alert
Daiichi Sankyo Ranbaxy Acquisition Very Much Alive
Details of tender offer at 40 percent premium revealed.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.